Jun 10, 2020 / 02:30PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone. Thanks for joining us. We're pleased to have Denali Therapeutics with us this morning. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And from Denali, we have Ryan Watts, Chief Executive Officer.
And with that, Ryan, I'm going to turn it over to you to make opening presentation, and then we can move it into Q&A.
Ryan J. Watts - Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
Great. Thank you, Salveen. Excellent to be here today. Looking forward to presenting. I'm going to share my slides now and spend some time on 3 of our programs today, starting with the blood-brain barrier technology, moving on to LRRK2 and then to RIP kinase. And so just quick disclaimers here. Just a reminder that Denali is focused on defeating degeneration. And so we have a number of ongoing or recently completed studies in rare neurodegenerative diseases; ALS, Parkinson's and Alzheimer's disease. The company is built on 2 platforms, what we
Denali Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers